chevron_leftBack
As of 13 June 2026, Indaptus Therapeutics, Inc. has a market cap of $6.53M USD, ranking #43375 globally and #5551 in the United States.
It ranks #3839 in the Healthcare sector, and #1238 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$6.53MUSD
Enterprise Value
-$1.67MUSD
EBITDA (TTM)
-$19.83MUSD
Net Income (TTM)
-$20.85MUSD
PB Ratio
2.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Junyi Dai
open_in_new
Employees
5
Founded
2000
Website
indaptusrx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -11% | -14% | 71% | 33% | -12% | -77% |
News
Loading...
INDP Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
INDP
Indaptus Therapeutics Inc
ISIN: US45339J2042
Shares Out.:
Shares Outstanding:
113.242M1
Shares Float:
3.464M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.91 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
12M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
8M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
6M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
4M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
2M%
|
19.5
|
|
NYSE: BMY
|
$117.58B
2M%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
5M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
4M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
4M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
3M%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
2M%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
2M%
80.96B GBP
|
14.6
|
chevron_leftBack